Back to MPT Database

Tenofovir IVR

Polyurethane, reservoir ring designed for up to 90 days use. First Phase I completed (CONRAD-128). Expanded Phase I trial (MTN-038) completed late 2019. The TFV IVR was also evaluated in comparison with oral Truvada for systemic and local PK and PD (CONRAD 140). A first-in-kind study to evaluate MPT IVRs in Africa (CDC Kisumu Combined Ring Study/CONRAD B17-44) was also completed late 2019.

Development Stage:

Clinical – Phase 2 Trial (C2)

Hormonal/Non-Hormonal:

Non-Contraceptive

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Mechanism of Action:

nucleoside analogue reverse transcriptase inhibitor (NRTI)

Developer:

  • CONRAD

Funding:

  • Centers for Disease Control and Prevention (CDC)
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)

Funding Mechanism:

NIH: Microbicide Trials Network (MTN)
USAID: Cooperative Agreement

Past Funding:

Bill & Melinda Gates Foundation
NIH: Interagency Agreements to USAID

Back to MPT Database